Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795326 | 0.89 | ELANE (0.79) | ELANELMNACA2RAB9AALOX15 | |
| SCHEMBL21325759 | 0.83 | ELANE (0.70) | ELANELMNACA2RAB9AALOX15 | |
| SCHEMBL891415 | 0.81 | ELANE (0.68) | ELANELMNAMEN1KMT2A | |
| SCHEMBL5186261 | 0.81 | ELANE (0.68) | ELANELMNACA2MAPTMEN1 | |
| SCHEMBL12616903 | 0.81 | ELANE (0.68) | ELANELMNACA2RAB9AMEN1 | |
| SCHEMBL80751 | 0.80 | LMNA (0.64) | ELANELMNARAB9APOLBMAPT | |
| SCHEMBL18211356 | 0.79 | ELANE (0.66) | ELANELMNARAB9AMAPTL3MBTL1 | |
| SCHEMBL4185924 | 0.79 | ELANE (0.66) | ELANELMNAMAPTMEN1KMT2A | |
| SCHEMBL4683823 | 0.79 | ELANE (0.66) | ELANELMNACA2MAPTPKM | |
| SCHEMBL12616891 | 0.79 | ELANE (0.66) | ELANELMNACA2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655392-B1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
| EP-1765844-B1 | PURINE NUCLEOTIDE DERIVATIVES | SOLVELL AS (NO) | 2014-07-30 | — | — | EP | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2655392-A1 | CYCLIC NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012088155-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20080293665-A1 | Purine Nucleotide Derivatives | LAURAS AS (NO) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | ELANE 647/4885LMNA 1635/4885CA2 4055/4885 |
| US-20080293665-A1 | Purine Nucleotide Derivatives | CGAS, PDE8A, PDE7A | ELANE 3668/4885LMNA 1707/4885CA2 3412/4885 |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | ELANE 647/4885LMNA 1635/4885CA2 4055/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | ELANE 647/4885LMNA 1635/4885CA2 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.